| Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients. | |
| | |
MedLine Citation:
|
PMID: 8004358 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with diabetes mellitus commonly exhibit pathological lipoprotein profiles and concomitant cardiovascular or peripheral atherosclerotic complications. Thirty non-insulin-dependent diabetics with secondary hyperlipidemia received 2.7 g 3-sn-polyenylphosphatidylcholine (PPC) or placebo daily, orally over a 2-month period under randomized, double-blind trial conditions, to investigate the efficacy and tolerance of the treatment. This period was followed by a one-month observation phase without investigational medication. Serum LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides were determined on days 1, 14, 28, 56 and 84. After 56 days of treatment with PPC, the primary variable of effectiveness, LDL cholesterol, decreased significantly (p = 0.0174) by 17% from 191 +/- 31 to 159 +/- 36 mg/dl, whereas values did not change in the placebo group. Total cholesterol (TC) in serum decreased by 16% from 303 +/- 22 to 255 +/- 23 mg/dl with PPC. In the placebo group, only a slight decrease from 292 +/- 27 to 289 +/- 41 mg/dl occurred. Mean serum triglyceride (TG) levels fell by 9% from 194 +/- 32 to 177 +/- 27 mg/dl in the PPC group. In the control group, values increased from 193 +/- 34 to 202 +/- 41 mg/dl. The differences in LDL, TC and TG between the treatment groups were statistically significant; p = 0.0014, p = 0.0001 and p = 0.007, respectively. HDL cholesterol in serum increased 12% from 50 +/- 10 to 55 +/- 13 mg/dl after PPC application. The control group did not show any alteration of mean HDL cholesterol level at any time.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
R Kirsten; B Heintz; K Nelson; K Hesse; E Schneider; G Oremek; N Nemeth |
Related Documents
:
|
3904378 - Secondary prevention and lipid lowering: results and implications. 20574598 - Ceramides and barrier function in healthy skin. 7185858 - Effect of high-chromium brewer's yeast on human serum lipids. 17327308 - Prevalence and treatment of low hdl cholesterol among primary care patients with type 2... 2851138 - Effect of low-fat, high-carbohydrate, high-fiber diet on fecal bile acids and neutral s... 2401718 - Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in ob... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: International journal of clinical pharmacology and therapeutics Volume: 32 ISSN: 0946-1965 ISO Abbreviation: Int J Clin Pharmacol Ther Publication Date: 1994 Feb |
Date Detail:
|
Created Date: 1994-07-18 Completed Date: 1994-07-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9423309 Medline TA: Int J Clin Pharmacol Ther Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 53-6 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, University of Frankfurt, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Aged Blood Glucose Cholesterol / blood Diabetes Mellitus, Type 2 / complications* Double-Blind Method Female Humans Hyperlipidemias / drug therapy*, etiology Male Middle Aged Phosphatidylcholines / administration & dosage, therapeutic use* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Phosphatidylcholines; 0/Triglycerides; 11096-62-1/lipostabil; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acute respiratory failure in patients treated for babesiosis.
Next Document: Lack of effect of Chinese medicines on bioavailability of ofloxacin in healthy volunteers.